The natural history of human papillomavirus infection

S de Sanjose, M Brotons, MA Pavon - Best practice & research Clinical …, 2018 - Elsevier
Human papillomavirus (HPV) is a small double-stranded DNA virus that commonly infects
humans. The oncogenic characteristics of HPV derive from the oncoproteins E6 and E7 that …

HPV and cervical cancer: A review of epidemiology and screening uptake in the UK

S Choi, A Ismail, G Pappas-Gogos, S Boussios - Pathogens, 2023 - mdpi.com
Cervical cancer is the fourth most common malignancy in females worldwide, and a leading
cause of death in the United Kingdom (UK). The human papillomavirus (HPV) is the …

Guidelines of care for the management of acne vulgaris

RV Reynolds, H Yeung, CE Cheng… - Journal of the American …, 2024 - Elsevier
Background Acne vulgaris commonly affects adults, adolescents, and preadolescents aged
9 years or older. Objective The objective of this study was to provide evidence-based …

Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?

S Mitra, MS Lami, A Ghosh, R Das, TE Tallei… - Cancers, 2022 - mdpi.com
Simple Summary The most common therapies for severe and recurrent gynecological
cancers are hormone therapy and chemotherapy, and responsiveness to therapy is a key …

High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early …

K Torres-Poveda, I Ruiz-Fraga, V Madrid-Marina… - Bmc Cancer, 2019 - Springer
Background Cervical cancer is the second cause leading of malignancy-related death
among Mexican women. The present study determined the population-based prevalence of …

Hormonal contraception and HIV-1 acquisition: biological mechanisms

JP Hapgood, C Kaushic, Z Hel - Endocrine reviews, 2018 - academic.oup.com
Access to effective affordable contraception is critical for individual and public health. A wide
range of hormonal contraceptives (HCs), which differ in composition, concentration of the …

The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women

H Hamoda, N Panay, H Pedder, R Arya… - Post reproductive …, 2020 - journals.sagepub.com
The British Menopause Society & Women’s Health Concern 2020 recommendations on
hormone replacement therapy in menopausal women - Haitham Hamoda, Nick Panay …

Current evidence of the oncological benefit-risk profile of hormone replacement therapy

M D'Alonzo, VE Bounous, M Villa, N Biglia - Medicina, 2019 - mdpi.com
Hormone replacement therapy (HRT) remains the most effective treatment for menopausal
symptoms and has been shown to prevent bone loss and fracture. The progestogen is …

Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis

VK Cortessis, M Barrett, NB Wade… - Obstetrics & …, 2017 - journals.lww.com
OBJECTIVE: To estimate the association between use of an intrauterine device (IUD) and
risk of cervical cancer by subjecting existing data to critical review, quantitative synthesis …

[HTML][HTML] The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals

AM Berner, SE Atkinson - Best Practice & Research Clinical Endocrinology …, 2024 - Elsevier
There is evidence that gender-affirming hormone treatment (GAHT) for transgender
individuals modulates their risk for specific malignancies including breast and prostate …